Table 1.
Clinical characteristics of 20 patients with PD-1 pneumonitis
| Pt | Tumor | Sex | Age | Agents | Treatment regimen and drug dosage | Time to the onset of pneumonitis (month) | Grade | Symptoms |
|---|---|---|---|---|---|---|---|---|
| 1 | Melanoma | M | 58 | Nivolumab | Nivolumab (1 mg/kg q2w) | 1.7 | 2 | Cough |
| 2 | Melanoma | F | 38 | Nivolumab | Nivolumab (3 mg/kg q2w) | 3.6 | 3 | Dyspnea, hypoxia |
| 3 | Melanoma | M | 70 | Nivolumab & ipilimumab | Nivolumab (3 mg/kg, q2w) × 6 then ipilimumab (3 mg/kg, q3w) × 4 | 5.6 | 3 | Cough, dyspnea, hypoxia, subacute fever |
| 4 | Melanoma | F | 66 | Nivolumab & ipilimumab | Nivolumab (3 mg/kg, q2w) × 6 then ipilimumab (3 mg/kg, q3w) × 4 | 5.4 | 1 | None |
| 5 | Melanoma | F | 40 | Nivolumab & ipilimumab | Nivolumab (3 mg/kg, q2w) × 6 then ipilimumab (3 mg/kg, q3w) × 4 | 7.3 | 2 | Cough, dyspnea |
| 6 | Melanoma | M | 64 | Nivolumab & ipilimumab | Nivolumab (3 mg/kg, q2w) × 6 then ipilimumab (3 mg/kg, q3w) × 4 | 3.7 | 2 | Cough, dyspnea |
| 7 | Melanoma | M | 57 | Nivolumab & ipilimumab | Nivolumab (1 mg/kg) & ipilimumab (3 mg/kg) q3w ×4, then nivolumab alone (3mg/kg, q2w) | 2.7 | 2 | Cough, dyspnea |
| 8 | Melanoma | F | 47 | Nivolumab & ipilimumab | Nivolumab (1 mg/kg) & ipilimumab (3 mg/kg) q3w ×4, then nivolumab alone (3mg/kg, q2w) | 2.4 | 1 | None |
| 9 | Melanoma | F | 35 | Nivolumab & ipilimumab | Nivolumab (1 mg/kg) & ipilimumab (3 mg/kg) q3w ×4, then nivolumab alone (3mg/kg, q2w) | 1.6 | 3 | Cough, dyspnea, fever |
| 10 | Melanoma | F | 52 | Nivolumab & ipilimumab | Nivolumab (1 mg/kg) & ipilimumab (3 mg/kg) q3w ×4, then nivolumab alone (3mg/kg, q2w) | 2.7 | 1 | None |
| 11 | Lung (Adenoca) | F | 56 | Nivolumab | Nivolumab (10 mg/kg, q2w) | 1.4 | 3 | Cough, dyspnea, fever |
| 12 | Lung (Adenoca) | F | 40 | Nivolumab | Nivolumab (1 mg/kg q2w) | 1.2 | 1 | None |
| 13 | Lung (Adenoca) | F | 52 | Nivolumab & lirilumab | Nivolumab (3 mg/kg, q2w) & Lirilumab (3 mg/kg, q4w) | 1.1 | 2 | Dyspnea, hypoxia |
| 14 | Lung (SCLC) | M | 59 | Nivolumab | Nivolumab 3 mg/kg q2w | 0.5 | 3 | Dyspnea, hypoxia |
| 15 | Lymphoma (Hodgkin) | F | 30 | Nivolumab & ipilimumab | Nivolumab (3mg/kg) & ipilimumab (1mg/kg) q3w × 4, then nivolumab (3 mg/kg q2w) | 11.5 | 2 | Cough |
| 16 | Lymphoma (Hodgkin) | F | 33 | Nivolumab & ipilimumab | Nivolumab (3mg/kg) &ipilimumab (1mg/kg) q3w × 4, then nivolumab (3 mg/kg q2w) | 1.4 | 2 | Cough, dyspnea |
| 17 | Lymphoma (Hodgkin) | F | 71 | Nivolumab & ipilimumab | Nivolumab (3mg/kg) & ipilimumab (1mg/kg) q3w × 4, then nivolumab (3 mg/kg q2w) | 1.4 | 2 | Cough, dyspnea |
| 18 | Lymphoma (T cell) | F | 62 | Nivolumab & ipilimumab | Nivolumab (3mg/kg) & ipilimumab (1mg/kg) q3w × 4, then nivolumab (3 mg/kg q2w) | 4.6 | 2 | Cough |
| 19 | Lymphoma (Hodgkin) | M | 30 | Nivolumab & lirilumab | Nivolumab (3mg/kg, q2w) & lirilumab (3 mg/kg, q4w) | 4.1 | 1 | None |
| 20 | Lymphoma (Hodgkin) | M | 28 | Nivolumab & lirilumab | Nivolumab (3mg/kg, q2w) & lirilumab (3 mg/kg, q4w) | 0.8 | 2 | Cough, fever |
Adecnoca: Adenocarcinoma
SCLC: small-cell lung cancer